Anticancer iridium(iii) cyclopentadienyl complexes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F25%3A73633963" target="_blank" >RIV/61989592:15310/25:73633963 - isvavai.cz</a>
Result on the web
<a href="https://pubs.rsc.org/en/content/articlelanding/2025/qi/d4qi02472a" target="_blank" >https://pubs.rsc.org/en/content/articlelanding/2025/qi/d4qi02472a</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1039/d4qi02472a" target="_blank" >10.1039/d4qi02472a</a>
Alternative languages
Result language
angličtina
Original language name
Anticancer iridium(iii) cyclopentadienyl complexes
Original language description
Platinum-based anticancer drugs have been highly effective at treating various cancers. While they have shown significant promise, their potential limitations have motivated researchers to explore other noble metal-based compounds, including iridium (Ir) complexes. Among these, half-sandwich Ir(iii) cyclopentadienyl (Ir-Cpx) complexes have emerged as promising new anticancer compounds. This relatively new area of bioinorganic chemistry has made significant progress since its inception in 2007, although no representative has yet entered clinical trials. Recent studies over the past 5-10 years have significantly advanced our understanding of the stability, speciation, intracellular localization, target organelles and molecular targets involved in the mechanisms of action (MoAs) of these compounds. This comprehensive review provides the reader with an overview of anticancer Ir-Cpx complexes and diverse chemical, biochemical and biological methods used for their research and development. Structure-activity relationships (SARs) and mechanisms of action (MoAs) are discussed with respect to anticancer activity and in comparison with their structurally similar ruthenium(ii), rhodium(iii) and osmium(ii) analogues. Considerable attention is paid to in vivo anticancer activity and related aspects, such as drug delivery strategies, multi-component drugs or photodynamic therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10402 - Inorganic and nuclear chemistry
Result continuities
Project
<a href="/en/project/NU22-08-00236" target="_blank" >NU22-08-00236: Pre-clinical study of non-platinum metalodrugs for lung cancer therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Inorganic Chemistry Frontiers
ISSN
2052-1545
e-ISSN
2052-1553
Volume of the periodical
12
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
58
Pages from-to
897-954
UT code for WoS article
001386345400001
EID of the result in the Scopus database
2-s2.0-85213039373